Company intelligence / Profile preview

TILAL MEDICAL COMPANY

Ownership: Private
Development stage: Other

Overview

Tilak Healthcare’s OdySight® app has demonstrated high concordance between home-based visual acuity measurements and standard clinical tests in the TIL002 study. The solution enables patients with chronic retinal diseases to self-monitor their vision at home, supporting timely intervention by clinicians. Over 15,000 patients have used the app in France, prescribed by more than 900 ophthalmologists. Clinical validation supports its reliability for remote patient management.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Digital Health Medical Devices

Partnerships

Laboratoires Théa (joint promotion of OdySight® in France)Voluntis/Aptar Pharma Digital Health (digital health partnership)

Beyond the preview

Go deeper on TILAL MEDICAL COMPANY.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TILAL MEDICAL COMPANY.

Explore the full profile